Monopar Therapeutics Operating Income Loss

• Monopar Therapeutics showed a decrease of -3.4% in Operating Income Loss from 2024 to 2025.
• This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Monopar Therapeutics's Operating Income Loss has declined by 1,300.4%.
• Historical annual values: Fiscal year 2025: -$16.70 million | Fiscal year 2024: -$16.16 million | Fiscal year 2023: -$8.83 million | Fiscal year 2022: -$10.54 million | Fiscal year 2021: -$9.13 million | Fiscal year 2020: -$6.51 million | Fiscal year 2019: -$4.32 million | Fiscal year 2018: -$3.33 million | Fiscal year 2017: -$16.60 million | Fiscal year 2016: -$1.19 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026